Median levels of IL-18 (25, 75 percentiles) as related to clinical endpoints.

<p>p-values are adjusted for age, gender, previous myocardial infarction (MI), stroke, treatment modality, and use of nitrates.</p

Circulating levels of MMP-9, TIMP-1 and EMMPRIN as related to MetS +/−.

<p>Levels are median (25, 75 percentiles).</p><p>^*<i>p</i><0.05 refers to difference in circulating levels of the markers between MetS +/−, adjusted for age and gender.</p><p>Circulating levels of MMP-9, TIMP-1 and EMMPRIN as related to MetS +/−.</p

Baseline characteristics according to occurrence of clinical composite endpoints after 2 years.

<p>Values are mean (SD) or number (proportions) if not otherwise stated. SD: standard deviation, BMI: body mass index, HDL: high density lipoprotein, LDL: low density lipoprotein, ACE: angiotensin converting enzyme, ARB: angiotensin receptor blocker, CCB: calcium channel blocker.</p><p><i>p</i>-values are chi-square test for categorical variables and <i>t</i>-test or Mann-Whitney test for continuous variables, referring to differences between patients with and without endpoints.</p>*<p>Median levels (25, 75 percentiles).</p

Tertiles of IL-18 as related to clinical endpoints.

<p>33 percentiles = 212.5 pg/mL, 66 percentiles = 293.1 pg/mL. p-values refer to the comparison of 2 groups dichotomized between second and third tertile. p-values are adjusted for age, gender, previous myocardial infarction (MI) and stroke, treatment modality and use of nitrates.</p

Baseline characteristics in the total population with and without the presence of MetS and in MetS patients according to clinical endpoints.

<p>Values are mean (SD) or number (proportions) if not otherwise stated. SD: standard deviation, MI: myocardial infarction, BMI: body mass index, HDL: high density lipoprotein.</p>a<p><i>p</i>-values refer to differences between patients with and without Mets,</p>b<p>p-values refer to differences between MetS patients with and without clinical endpoint.</p>c<p>Median levels (25, 75 percentiles).</p><p>Baseline characteristics in the total population with and without the presence of MetS and in MetS patients according to clinical endpoints.</p

Influence of the MMP-9 −1562 C/T polymorphism on clinical events in CAD patients with MetS.

<p><b>A. Number (%) of Composite clinical endpoints in CAD patients as related to the MMP-9 −1562 C/T polymorphism and MetS +/−.</b> White bars: MetS – (CC n = 63, T-allele n = 18), black bars: MetS + (CC n = 10, T-allele n = 15) <i>p</i>-values refer to risk of endpoints in T-allele carriers as compared to the CC genotype. ^* adjusted for age and gender. <b>B. Number (%) of Composite clinical endpoints in CAD patients as related to the MMP-9 −1562 C/T polymorphism and number of MetS criteria.</b> White bars: CC genotype, black bars: T-allele. <i>p</i>-values refer to risk of endpoints in T-allele carriers as compared to CC genotype when MetS criteria are categorized into 3 groups; 0 and 1 MetS criteria (CC n = 46, T-allele n = 9), 2 and 3 MetS criteria (CC n = 24, T-allele n = 14), and 4 and 5 Mets criteria (CC n = 3, CT n = 10). ^* adjusted for age and gender.</p

Circulating MMP-9 levels according to clinical events and the MMP-9 −1562 C/T polymorphism.

<p><b>A. Tertiles of total MMP-9 levels as related to Composite clinical endpoints and MetS +/−.</b> White bars: Tertile 1, grey bars: Tertile 2, black bars: Tertile 3. 33percentile  = 186.9 ng/mL, 66 percentiles  = 305.8 ng/mL. The number in each Tertile group (1-2-3) in MetS; 1-14-10, in non-MetS; 33-23-25. <i>p</i>-values refer to the comparison of groups dichotomized between the lowest and the two upper tertiles. ^* adjusted for age and gender. <b>B. Circulating levels of total MMP-9 according to different MMP-9 −1562 C/T genotypes in MetS +/−.</b> White bars: CC genotype, grey bars: CT genotype, black bars: TT genotype. The number in each genotype group CC-CT-TT in MetS; 182- 60- 2, in non-MetS; 573-165-13. <i>p</i>-values refer to difference in circulating MMP-9 levels according to MMP-9 -1562 genotypes, Kruskal Wallis test.</p

Frequencies of the IL-18+183 A/G and MMP-9 -1562 C/T polymorphisms, as related to clinical endpoints.

<p><i>p</i>-values refer to difference in frequencies of the IL-18/MMP-9 polymorphisms alone and in combination, as related to clinical endpoints.</p>*<p>Adjusted for age, gender, previous MI, stroke, treatment modality, and use of nitrates.</p>#<p>OR 0.65 (95% CI 0.43, 0.99).</p>†<p>OR 1.87 (95% CI 1.13, 3.11).</p>‡<p>OR 2.54 (95% CI 1.07, 6.00).</p

Supplemental Material, Revised_Supplementary_File_FINAL - Markers of Thrombin Generation Are Associated With Long-Term Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction

<p>Supplemental Material, Revised_Supplementary_File_FINAL for Markers of Thrombin Generation Are Associated With Long-Term Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction by Charlotte Holst Hansen, Vibeke Ritschel, Geir Øystein Andersen, Sigrun Halvorsen, Jan Eritsland, Harald Arnesen, and Ingebjørg Seljeflot in Clinical and Applied Thrombosis/Hemostasis</p

Patient characteristics at inclusion, stratified to levels of IL-8 ≤ or > median value.

<p>Continuous data are presented as median (IQR) unless indicated otherwise. MI, myocardial infarction; IABP, intra-aortic balloon counter-pulsation; TnT, troponin T; BP, blood pressure; CRP, C-reactive protein, NT-proBNP, N-terminal pro B-type natriuretic peptide; WMSI, wall motion score index; LVEF, left ventricular ejection fraction; ACE-inh, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker.</p><p>Patient characteristics at inclusion, stratified to levels of IL-8 ≤ or > median value.</p